Insider Buying: PureTech Health (LON:PRTC) Insider Buys £939.44 in Stock

PureTech Health plc (LON:PRTC) insider John LaMattina purchased 93,944 shares of the stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average cost of GBX 1 per share, for a total transaction of £939.44.

John LaMattina also recently made the following trade(s):

• On Wednesday, July 8th, John LaMattina acquired 50,000 shares of PureTech Health stock. The shares were acquired at an average cost of GBX 119 per share, for a total transaction of £59,500.

PureTech Health Price Performance

LON PRTC opened at GBX 119.12 on Monday. PureTech Health plc has a one year low of GBX 104.71 and a one year high of GBX 146.40. The stock has a 50-day moving average of GBX 127.34 and a 200 day moving average of GBX 126.62. The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59. The company has a market capitalization of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79.

Analysts Set New Price Targets

Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 508 price target on shares of PureTech Health in a research note on Monday, July 13th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of GBX 508.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.